This previous process, which prioritised the need to secure broad industry support for reforms, has been displaced by a system of layered privilege. This is partly due to the government's more aggressive and impatient approaches to reform and partly because the industry has become more acquiescent.
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News


